Disclosures for "Safety, Tolerability, and Efficacy of Brexpiprazole for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease: A 12-week Extension Trial"
-
Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BioXcel. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Karuna. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Otsuka. The institution of Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Anavex. The institution of Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EryDel. The institution of Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Newron. The institution of Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for acadia. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for biogen. Dr. Grossberg has received publishing royalties from a publication relating to health care. Dr. Grossberg has received publishing royalties from a publication relating to health care.
-
Dr. Lee has received personal compensation for serving as an employee of Otsuka.
-
Dr. Slomkowski has received personal compensation for serving as an employee of Otsuka.
-
Mr. Hefting has received personal compensation for serving as an employee of H. Lundbeck A/S. Mr. Hefting has stock in H. Lundbeck A/S. Mr. Hefting has stock in Novo nordisk A/S.
-
Dr. Chen has nothing to disclose.
-
Mary Hobart has received personal compensation for serving as an employee of Otsuka Pharmaceutical Development & Commercialization, Inc..
-
Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ACADIA. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alkahest. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche/Genentech. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Green Valley. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Otsuaka. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for United Neuroscience. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Cummings has received research support from NIH. Dr. Cummings has received intellectual property interests from a discovery or technology relating to health care.